-
Je něco špatně v tomto záznamu ?
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
T. Bochenek, V. Abilova, A. Alkan, B. Asanin, I. de Miguel Beriain, Z. Besovic, P. Vella Bonanno, A. Bucsics, M. Davidescu, E. De Weerdt, N. Duborija-Kovacevic, J. Fürst, M. Gaga, E. Gailīte, J. Gulbinovič, EU. Gürpınar, B. Hankó, V. Hargaden,...
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
29403372
DOI
10.3389/fphar.2017.00942
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, compare, and evaluate the current systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages within health care systems across a range of European and Western Asian countries. The study design was retrospective, cross-sectional, descriptive, and observational. Information was gathered through a survey distributed among senior personnel from ministries of health, state medicines agencies, local health authorities, other health or pharmaceutical pricing and reimbursement authorities, health insurance companies and academic institutions, with knowledge of the pharmaceutical markets in the 28 countries studied. Our study found that formal definitions of drug shortages currently exist in only a few countries. The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess. Numerous information hubs were identified. Providing public access to information on drug shortages to the maximum possible extent is a prerequisite for performing more advanced studies on the problem and identifying solutions. Imposing public service obligations, providing the formal possibility to prescribe unlicensed medicines, and temporary bans on parallel exports are widespread measures. A positive finding of our study was the identification of numerous bottom-up initiatives and organizational frameworks aimed at preventing or mitigating drug shortages. The experiences and lessons drawn from these initiatives should be carefully evaluated, monitored, and presented to a wider international audience for careful appraisal. To be able to find solutions to the problem of drug shortages, there is an urgent need to develop a set of agreed definitions for drug shortages, as well as methodologies for their evaluation and monitoring. This is being progressed.
7th Respiratory Medicine Department Athens Chest Hospital Sotiria Athens Greece
Agency for Medicinal Products and Medicinal Devices Ljubljana Slovenia
Analytical Expertise Centre Ministry of Health Baku Azerbaijan
Chania General Hospital Crete Greece
Clalit Health Services Headquarters Tel Aviv Israel
Clinical Centre of Serbia Belgrade Serbia
CNAMTS Statutory Health Insurance for Salaried Workers Paris France
Croatian Health Insurance Fund Zagreb Croatia
Dentons Europe Dąbrowski i Wspólnicy sp k Warszawa Poland
Department of Drug Management Faculty of Pharmacy UBT Prishtina Albania
Department of Medicines Health Insurance Institute Ljubljana Slovenia
Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium
Department of Pharmacy University of Medicine Tirana Albania
Estonian State Agency of Medicines Tartu Estonia
Graduate School of Business Administration Bar Ilan University Ramat Gan Israel
Institute of Orthopaedic Surgery Banjica Belgrade Serbia
Local Health Unit of Verona Veneto Region Verona Italy
Mechanism of Coordinated Access to Orphan Medicinal Products Brussels Belgium
Norwegian Medicines Agency Oslo Norway
RG Chair in Law and the Human Genome University of the Basque Country Leioa Spain
School of Mechanical and Materials Engineering University College Dublin Dublin Ireland
State Agency of Medicines Riga Latvia
State Agency of Medicines Tartu Estonia
State Institute for Drug Control Prague Czechia
Turkish Medicines and Medical Devices Agency Ankara Turkey
University Pharmacy Department of Pharmacy Administration Semmelweis University Budapest Hungary
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010028
- 003
- CZ-PrNML
- 005
- 20210316130604.0
- 007
- ta
- 008
- 180404s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2017.00942 $2 doi
- 035 __
- $a (PubMed)29403372
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bochenek, Tomasz $u Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
- 245 10
- $a Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries / $c T. Bochenek, V. Abilova, A. Alkan, B. Asanin, I. de Miguel Beriain, Z. Besovic, P. Vella Bonanno, A. Bucsics, M. Davidescu, E. De Weerdt, N. Duborija-Kovacevic, J. Fürst, M. Gaga, E. Gailīte, J. Gulbinovič, EU. Gürpınar, B. Hankó, V. Hargaden, TA. Hotvedt, I. Hoxha, I. Huys, A. Inotai, A. Jakupi, H. Jenzer, R. Joppi, O. Laius, MC. Lenormand, D. Makridaki, A. Malaj, K. Margus, V. Marković-Peković, N. Miljković, JL. de Miranda, S. Primožič, D. Rajinac, DG. Schwartz, R. Šebesta, S. Simoens, J. Slaby, L. Sović-Brkičić, T. Tesar, L. Tzimis, E. Warmińska, B. Godman,
- 520 9_
- $a Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, compare, and evaluate the current systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages within health care systems across a range of European and Western Asian countries. The study design was retrospective, cross-sectional, descriptive, and observational. Information was gathered through a survey distributed among senior personnel from ministries of health, state medicines agencies, local health authorities, other health or pharmaceutical pricing and reimbursement authorities, health insurance companies and academic institutions, with knowledge of the pharmaceutical markets in the 28 countries studied. Our study found that formal definitions of drug shortages currently exist in only a few countries. The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess. Numerous information hubs were identified. Providing public access to information on drug shortages to the maximum possible extent is a prerequisite for performing more advanced studies on the problem and identifying solutions. Imposing public service obligations, providing the formal possibility to prescribe unlicensed medicines, and temporary bans on parallel exports are widespread measures. A positive finding of our study was the identification of numerous bottom-up initiatives and organizational frameworks aimed at preventing or mitigating drug shortages. The experiences and lessons drawn from these initiatives should be carefully evaluated, monitored, and presented to a wider international audience for careful appraisal. To be able to find solutions to the problem of drug shortages, there is an urgent need to develop a set of agreed definitions for drug shortages, as well as methodologies for their evaluation and monitoring. This is being progressed.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Abilova, Vafa $u Analytical Expertise Centre, Ministry of Health, Baku, Azerbaijan.
- 700 1_
- $a Alkan, Ali $u Turkish Medicines and Medical Devices Agency, Ankara, Turkey.
- 700 1_
- $a Asanin, Bogdan $u Department of Surgery, Department of Medical Ethics, Medical Faculty of the University of Montenegro, Podgorica, Montenegro.
- 700 1_
- $a de Miguel Beriain, Iñigo $u RG Chair in Law and the Human Genome, University of the Basque Country, Leioa, Spain.
- 700 1_
- $a Besovic, Zeljka $u Montenegrin Agency for Drugs and Medical Devices, Sector for Drugs and Medical Devices, Podgorica, Montenegro.
- 700 1_
- $a Vella Bonanno, Patricia $u Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
- 700 1_
- $a Bucsics, Anna $u Mechanism of Coordinated Access to Orphan Medicinal Products, Brussels, Belgium.
- 700 1_
- $a Davidescu, Michal $u Clalit Health Services Headquarters, Tel-Aviv, Israel.
- 700 1_
- $a De Weerdt, Elfi $u Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Duborija-Kovacevic, Natasa $u Department of Pharmacology and Clinical Pharmacology, Medical Faculty of the University of Montenegro, Podgorica, Montenegro.
- 700 1_
- $a Fürst, Jurij $u Department of Medicines, Health Insurance Institute, Ljubljana, Slovenia.
- 700 1_
- $a Gaga, Mina $u 7th Respiratory Medicine Department, Athens Chest Hospital Sotiria, Athens, Greece.
- 700 1_
- $a Gailīte, Elma $u State Agency of Medicines, Riga, Latvia.
- 700 1_
- $a Gulbinovič, Jolanta $u Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Vilnius, Lithuania. State Medicine Control Agency, Vilnius, Lithuania.
- 700 1_
- $a Gürpınar, Emre U $u Turkish Medicines and Medical Devices Agency, Ankara, Turkey.
- 700 1_
- $a Hankó, Balázs $u University Pharmacy Department of Pharmacy Administration, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Hargaden, Vincent $u School of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland.
- 700 1_
- $a Hotvedt, Tor A $u Norwegian Medicines Agency, Oslo, Norway.
- 700 1_
- $a Hoxha, Iris $u Department of Pharmacy, University of Medicine, Tirana, Albania.
- 700 1_
- $a Huys, Isabelle $u Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Inotai, Andras $u Syreon Research Institute, Budapest, Hungary. Department of Health Policy and Health Economics, Institute of Economics, Eötvös Loránd University, Budapest, Hungary.
- 700 1_
- $a Jakupi, Arianit $u Department of Drug Management, Faculty of Pharmacy, UBT (Kosovo), Prishtina, Albania.
- 700 1_
- $a Jenzer, Helena $u Health Department, Bern University of Applied Sciences, Bern, Switzerland. University Hospital of Psychiatry Zurich (PUK), Zurich, Switzerland.
- 700 1_
- $a Joppi, Roberta $u Local Health Unit of Verona-Veneto Region, Verona, Italy.
- 700 1_
- $a Laius, Ott $u State Agency of Medicines, Tartu, Estonia.
- 700 1_
- $a Lenormand, Marie-Camille $u CNAMTS, Statutory Health Insurance for Salaried Workers, Paris, France.
- 700 1_
- $a Makridaki, Despina $u Panhellenic Association of Hospital Pharmacists, Athens, Greece. National Organization for Medicines, Athens, Greece.
- 700 1_
- $a Malaj, Admir $u Department of Pharmacy, University of Medicine, Tirana, Albania.
- 700 1_
- $a Margus, Kertu $u Estonian State Agency of Medicines, Tartu, Estonia.
- 700 1_
- $a Marković-Peković, Vanda $u Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina. Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka (Republic of Srpska), Banja Luka, Bosnia and Herzegovina.
- 700 1_
- $a Miljković, Nenad $u Institute of Orthopaedic Surgery Banjica, Belgrade, Serbia.
- 700 1_
- $a de Miranda, João L $u Escola Superior de Tecnologia e Gestão, Instituto Politécnico de Portalegre, Portalegre, Portugal. Centro de Recursos Naturais e Ambiente, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
- 700 1_
- $a Primožič, Stanislav $u Agency for Medicinal Products and Medicinal Devices, Ljubljana, Slovenia.
- 700 1_
- $a Rajinac, Dragana $u Clinical Centre of Serbia, Belgrade, Serbia.
- 700 1_
- $a Schwartz, David G $u Graduate School of Business Administration, Bar-Ilan University, Ramat-Gan, Israel.
- 700 1_
- $a Šebesta, Robin $u State Institute for Drug Control, Prague, Czechia.
- 700 1_
- $a Simoens, Steven $u Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Slaby, Juraj $u State Institute for Drug Control, Prague, Czechia.
- 700 1_
- $a Sović-Brkičić, Ljiljana $u Croatian Health Insurance Fund, Zagreb, Croatia.
- 700 1_
- $a Tesar, Tomas $u Department of Organisation and Management in Pharmacy, Pharmaceutical Faculty, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Tzimis, Leonidas $u Chania General Hospital, Crete, Greece.
- 700 1_
- $a Warmińska, Ewa $u Dentons Europe Dąbrowski i Wspólnicy sp. k., Warszawa, Poland.
- 700 1_
- $a Godman, Brian $u Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom. Division of Clinical Pharmacology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Health Economics Centre, Liverpool University Management School, Liverpool, United Kingdom.
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 8, č. - (2018), s. 942
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29403372 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20210316130600 $b ABA008
- 999 __
- $a ind $b bmc $g 1287513 $s 1006840
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 8 $c - $d 942 $e 2017 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20180404
